U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168824) titled 'An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition' on Sept. 04.
Brief Summary: This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to evaluate the effects of probiotics on blood-related biomarkers.
Study Start Date: Sept. 10
Study Type: INTERVENTIONAL
Condition:
Subjective Cognitive Decline (SCD)
Intervention:
DIETARY_SUPPLEMENT: Lacticaseibacillus paracasei
one capsule daily for 12 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chi-C...